#USA #Montreal #Zemcelpro #ExCellThera #Avanzanite

ExCellThera and Avanzanite: Pioneering New Horizons for Zemcelpro® in Europe

ExCellThera Inc., a frontrunner in blood stem cell expansion technologies, recently made a significant announcement about its exclusive licensing and supply agreements with Avanzanite Bioscience B.V., marking a monumental step for its groundbreaking product, Zemcelpro® (dorocubicel), also recognized as UM171 Cell Therapy. This agreement opens the door to commercializing this innovative therapy across 32 nations within the European Economic Area, the UK, and Switzerland.

Zemcelpro® presents a pioneering approach to hematological disorders by offering a personalized cryopreserved stem cell transplantation option. It involves two vital cellular components: UM171-expanded CD34+ cells and unexpanded CD34- cells, both sourced from the same cord blood unit. The therapy targets patients afflicted with hematological malignancies, such as leukemias and myelodysplastic syndromes, particularly those needing allogeneic transplantation but lacking a suitable donor.

The CEO of Cordex, David Millette, emphasized the agreement with Avanzanite as a crucial step towards addressing unmet medical needs in Europe. “These agreements represent an important milestone in advancing our global commercialization strategy for Zemcelpro®,” Millette stated. He highlighted Avanzanite's expertise and extensive presence across the European landscape, suggesting that their strategic fit would be instrumental in expanding patient access to this vital therapy.

Avanzanite, founded in 2022 and headquartered in Amsterdam, is dedicated to enhancing the availability of innovative medicines for rare diseases. This partnership embodies Avanzanite's mission to unlock the full potential of groundbreaking therapies, a vision shared with ExCellThera. Co-founder and CEO of Avanzanite, Adam Plich, accentuated the vital need to deliver Zemcelpro® to those suffering from blood cancers, reinforcing their commitment to ensuring that no patient goes without necessary treatment options.

The licensing agreement is multifaceted, encompassing development fees, commercial milestone payments, and royalties. This structure creates a foundation for both companies to share in the long-term commercial success of Zemcelpro®. Furthermore, it facilitates funding for a forthcoming Phase 3 trial that will evaluate Zemcelpro® in patients grappling with high- and very high-risk acute leukemias and myelodysplastic syndromes. This pivotal trial aims to generate essential efficacy and safety data, potentially expanding the therapy’s indications in the future.

In terms of logistics, Avanzanite will spearhead regulatory activities, market access strategies, pricing, reimbursement, medical affairs, commercial operations, and product distribution throughout the licensed territories. Following the regulatory transfer, Avanzanite will take over the existing EU marketing authorization for Zemcelpro®, which illustrates a collaborative drive toward enhancing market responsiveness.

While Avanzanite will handle regulatory responsibilities in European territories, Cordex will maintain its role in globally developing Zemcelpro® and ensuring its manufacturing and supply chain processes remain stringent and efficient.

About Zemcelpro®

Zemcelpro® (dorocubicel) is recognized as a novel approach in the realm of hematopoietic stem cell transplantation. It has gained conditional marketing authorization from the European Commission, particularly aimed at aiding adult patients in dire need of this innovative treatment following rigorous conditioning protocols. Clinical evaluations have demonstrated its efficacy across over 120 patients with hematological malignancies across multiple trials in North America and Europe.

The ongoing investigational pathways include additional regulatory submissions to health authorities in Canada and the US, with aspirations for broader applications involving pediatric patients and those with non-malignant hematological disorders.

In conclusion, the strategic partnership between ExCellThera and Avanzanite not only signifies a progress in therapeutic options available for European patients battling blood cancers, but it also represents a collaborative effort to address the urgent medical needs in an evolving healthcare landscape. As both companies work in unison to navigate the intricacies of regulatory frameworks and market access, patients awaiting this life-saving therapy may soon find renewed hope through the endeavors of Zemcelpro®.